Compare Accenture plc (ACN) vs Sanofi SA (SNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Accenture plc vs Sanofi SA — how do they compare? Accenture plc trades at $138.53 (market cap $86.98B), while Sanofi SA trades at $43.05 (market cap $103.29B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.63%). Which is the better fit depends on your goals.
| ACN | SNY | |
|---|---|---|
Market Cap | $86.98B | $103.29B |
Sector | Technology | Health |
52-Week High | $303.33 | $52.34 |
52-Week Low | $124.41 | $41.33 |
Enterprise Value | $85.20B | $119.78B |
Dividend Yield | 4.59% | 5.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $136.96, down 0.28% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company reported strong revenue growth to $69.67B in 2025 with a net margin of 10.66%, supported by strategic AI partnerships announced in June 2026. Valuation ratios appear attractive with a P/E of 10.94 and EV/EBITDA of 6.65, while analyst consensus remains strongly bullish with a $193.92 price target.
The outlook is positive given consistent earnings outperformance, expanding AI-driven consulting partnerships, and solid cash flow generation. Key risks include competitive pressures in consulting services, execution challenges in integrating AI initiatives, and potential macroeconomic headwinds affecting client spending. The stock offers fundamental value with growth catalysts from digital transformation demand.
SNY trades at $42.98, down 0.42% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q1 2026 results with EPS of $1.10 beating expectations of $1.06, continuing a trend of positive surprises. Revenue grew to $46.72 billion in 2025 with net income margin improving to 16.72%. Recent developments include EU approval for Cenrifki in multiple sclerosis and FDA approval for Tzield expansion in pediatric diabetes treatment.
SNY presents a mixed investment case with solid fundamentals offset by technical weakness. The stock trades at reasonable valuations (P/E 18.9, P/S 1.92) with strong profitability metrics, but faces near-term headwinds from an antitrust probe and bearish technical indicators. Analyst consensus leans neutral with 44% buy ratings, suggesting cautious optimism amid regulatory uncertainties and pipeline execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
